MA45234A - Anticorps anti-facteur xi de coagulation - Google Patents

Anticorps anti-facteur xi de coagulation

Info

Publication number
MA45234A
MA45234A MA045234A MA45234A MA45234A MA 45234 A MA45234 A MA 45234A MA 045234 A MA045234 A MA 045234A MA 45234 A MA45234 A MA 45234A MA 45234 A MA45234 A MA 45234A
Authority
MA
Morocco
Prior art keywords
antibody
coagulation factor
coagulation
factor
Prior art date
Application number
MA045234A
Other languages
English (en)
French (fr)
Inventor
Zhu Chen
Kenneth P Ellsworth
Vaishnavi Ganti
James Milligan
Elizabeth Oldham
Bianka Prinz
Dietmar Seiffert
Mohammad Tabrizifard
Original Assignee
Adimab Llc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc, Merck Sharp & Dohme filed Critical Adimab Llc
Publication of MA45234A publication Critical patent/MA45234A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045234A 2016-06-14 2017-06-12 Anticorps anti-facteur xi de coagulation MA45234A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14

Publications (1)

Publication Number Publication Date
MA45234A true MA45234A (fr) 2019-04-17

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045234A MA45234A (fr) 2016-06-14 2017-06-12 Anticorps anti-facteur xi de coagulation

Country Status (29)

Country Link
US (6) US10676536B2 (enExample)
EP (1) EP3469002A1 (enExample)
JP (2) JP7022081B2 (enExample)
KR (2) KR102379580B1 (enExample)
CN (2) CN109476758B (enExample)
AR (1) AR108717A1 (enExample)
AU (3) AU2017286432B2 (enExample)
BR (1) BR112018075858A2 (enExample)
CA (2) CA3025869C (enExample)
CL (2) CL2018003565A1 (enExample)
CO (1) CO2018013434A2 (enExample)
CR (1) CR20180583A (enExample)
DO (1) DOP2018000284A (enExample)
EA (1) EA201892716A1 (enExample)
EC (1) ECSP18091593A (enExample)
GE (2) GEAP202114983A (enExample)
IL (2) IL263272B2 (enExample)
JO (1) JOP20180121A1 (enExample)
MA (1) MA45234A (enExample)
MX (2) MX2018015757A (enExample)
MY (1) MY201852A (enExample)
NI (1) NI201800134A (enExample)
PE (1) PE20190416A1 (enExample)
PH (1) PH12018502586A1 (enExample)
SG (2) SG10202103120UA (enExample)
TN (1) TN2018000417A1 (enExample)
TW (2) TWI802193B (enExample)
UA (1) UA129793C2 (enExample)
WO (1) WO2017218371A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
MY201852A (en) * 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
KR20230034361A (ko) * 2020-07-02 2023-03-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도
KR20230035079A (ko) * 2020-07-03 2023-03-10 수조우 알파맵 씨오., 엘티디. 응고인자 xi(fxi) 결합 단백질
AU2022219476A1 (en) * 2021-02-09 2023-09-21 Arxx Therapeutics As Anti-s100a4 humanized antibodies, uses and methods
EP4442273A4 (en) * 2021-11-30 2025-12-24 Suzhou Alphamab Co Ltd METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLIC DISEASES
EP4644426A1 (en) * 2022-12-30 2025-11-05 Gan & Lee Pharmaceuticals Co., Ltd. Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
EP1259615B1 (en) 2000-03-03 2008-11-12 Cambridge Antibody Technology Limited Antibodies against eotaxin and their use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
MEP31508A (hr) 2003-07-15 2010-10-10 Amgen Inc Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade
EA016022B1 (ru) 2004-12-21 2012-01-30 Сентокор, Инк. Выделенное антитело млекопитающего против il-12 и способ изменения его активности
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1960434B1 (en) 2005-12-08 2012-07-11 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
AU2006321841C1 (en) 2005-12-08 2013-01-24 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
KR20090039739A (ko) 2006-08-03 2009-04-22 아스트라제네카 아베 αＶβ６에 대해 작용하는 항체 및 그의 용도
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
CA2732003A1 (en) 2008-07-31 2010-02-04 James D. Marks Antibodies that neutralize botulinum neurotoxins
EA201500316A1 (ru) 2008-10-31 2016-01-29 Сентокор Орто Байотек Инк. Антагонисты толл-подобного рецептора 3
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
LT2373691T (lt) 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
AU2010236256C1 (en) 2009-04-16 2015-10-22 Abbvie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
EP2488553B1 (en) 2009-10-12 2015-06-17 Pfizer Inc. Cancer treatment
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
US9045536B2 (en) 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
EP2532151A2 (en) * 2010-02-03 2012-12-12 Trilogy IP Holdings, Inc. Mobile communication plan offerings
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
PL2650310T3 (pl) 2012-04-13 2017-01-31 Rottapharm Biotech S.R.L. Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
CN104918956A (zh) 2012-05-17 2015-09-16 索伦托治疗有限公司 与egfr结合的抗原结合蛋白
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US20160319032A1 (en) 2013-10-01 2016-11-03 Medlmmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
EP3121273A4 (en) 2014-03-20 2017-08-30 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Antibody having infection-inhibiting activity against hepatitis c virus
NZ726911A (en) 2014-06-03 2023-01-27 Xbiotech Inc Compositions and methods for treating and preventing staphylococcus aureus infections
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
JP7628764B2 (ja) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
RU2021129189A (ru) 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
MY201852A (en) 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies
EP4413996A3 (en) 2016-09-20 2024-10-23 Aronora, Inc. Novel antibodies against factor xi and uses thereof

Also Published As

Publication number Publication date
IL263272A (en) 2018-12-31
CR20180583A (es) 2019-07-02
TWI802193B (zh) 2023-05-11
SG10202103120UA (en) 2021-05-28
US12275800B2 (en) 2025-04-15
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
AU2020210233B2 (en) 2024-03-07
US20170355780A1 (en) 2017-12-14
TW201802120A (zh) 2018-01-16
UA129793C2 (uk) 2025-08-06
EA201892716A1 (ru) 2019-05-31
CN116425879A (zh) 2023-07-14
PH12018502586A1 (en) 2019-10-07
MX2018015757A (es) 2019-05-30
CN109476758A (zh) 2019-03-15
NZ786443A (en) 2025-06-27
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
NZ786444A (en) 2025-06-27
IL315266A (en) 2024-10-01
US11512142B2 (en) 2022-11-29
KR102218714B1 (ko) 2021-02-24
IL263272B2 (en) 2025-07-01
AU2017286432B2 (en) 2020-09-24
KR20190018504A (ko) 2019-02-22
CA3025869A1 (en) 2017-12-21
CL2024000367A1 (es) 2024-08-23
NZ748743A (en) 2025-06-27
US20200255542A1 (en) 2020-08-13
JP7277500B2 (ja) 2023-05-19
WO2017218371A1 (en) 2017-12-21
NZ786442A (en) 2025-06-27
KR102379580B1 (ko) 2022-03-29
US11485794B2 (en) 2022-11-01
TWI752964B (zh) 2022-01-21
DOP2018000284A (es) 2019-01-31
JOP20180121A1 (ar) 2018-12-12
AR108717A1 (es) 2018-09-19
CL2018003565A1 (es) 2019-03-22
TN2018000417A1 (en) 2020-06-15
US20200317811A1 (en) 2020-10-08
KR20210021124A (ko) 2021-02-24
CA3025869C (en) 2025-10-07
CO2018013434A2 (es) 2018-12-28
PE20190416A1 (es) 2019-03-19
JP2019521978A (ja) 2019-08-08
US11479615B2 (en) 2022-10-25
US20200308302A1 (en) 2020-10-01
EP3469002A1 (en) 2019-04-17
US20200270364A1 (en) 2020-08-27
TW202214702A (zh) 2022-04-16
NZ786447A (en) 2025-06-27
GEP20227382B (en) 2022-05-25
CA3172367A1 (en) 2017-12-21
ECSP18091593A (es) 2019-01-31
MX2023012740A (es) 2024-02-23
IL263272B1 (en) 2025-03-01
NI201800134A (es) 2019-03-05
AU2017286432A1 (en) 2018-12-06
JP7022081B2 (ja) 2022-02-17
NZ786448A (en) 2025-06-27
MY201852A (en) 2024-03-20
BR112018075858A2 (pt) 2019-04-02
JP2021101720A (ja) 2021-07-15
AU2020210233A1 (en) 2020-08-20
GEAP202114983A (en) 2021-12-10
SG11201810763TA (en) 2018-12-28
US11661460B2 (en) 2023-05-30

Similar Documents

Publication Publication Date Title
MA43660A (fr) Anticorps anti-facteur xi de coagulation
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
FR25C1022I2 (fr) Anticorps anti-pd-1
EP3498840A4 (en) ANTI-LAG-3 ANTIBODY
EP3423089A4 (en) ANTI-Tigit ANTIBODY
MA49034A (fr) Anticorps anti-lag3
MA47694A (fr) Anticorps anti-tigit
EP3334757A4 (en) ANTI-Tigit ANTIBODY
EP3297671A4 (en) ANTI-ROR1 ANTIBODY
MA47268A (fr) Anticorps anti-gpc3
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
MA53297A (fr) Anticorps anti-icos
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA47472A (fr) Anticorps
MA42626A (fr) Nouveaux anticorps anti-pd-1
DK3529269T3 (da) Antistof-konstruktioner
EP3492591A4 (en) ANTI-B7-H4 ANTIBODIES
EP3526247A4 (en) Anti-il1-rap antibodies
EP3581587A4 (en) Anticoagulant FACTOR XI ANTIBODY
HUE060878T2 (hu) Anti-transztiretin antitestek
EP3383915A4 (en) PD-1 ANTIBODY
EP3399992A4 (en) SELF-NETWORKING ANTIBODIES
EP3484919A4 (en) ANTIBODIES AGAINST AMYLOID BETA
IL263272A (en) Anti-coagulation factor xi antibodies
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY